Nasdaq

TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML

Filing is supported by strong clinical data and IND enabling pre-clinical data associated withTCB-008 in treatment of Acute Myeloid Leukemia The IND application leverages pioneering research on the ...
Nasdaq

TC BioPharm's IND Application For TCB-008 In Acute Myeloid Leukemia Gets FDA Clearance

(RTTNews) - TC BioPharm (Holdings) Plc. (TCBP) Monday announced that the FDA provided clearance on an investigational new drug application for a Phase 1B study in relapse/refractory Acute Myeloid ...